World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
50557
World Ranking
6164
National Ranking
3291

Overview

Stephen R. Marder is affiliated with the University of California, Los Angeles in the United States. Their primary research focus lies within the field of Medicine, particularly emphasizing Psychiatry and Mental Health. Contributions to Biological Psychiatry, Pharmacology, Experimental and Cognitive Psychology, and Social Psychology further characterize their multidisciplinary approach.

The main topics covered in Marder's research include:

  • Schizophrenia research and treatment
  • Bipolar Disorder and Treatment
  • Tryptophan and brain disorders
  • Mental Health Treatment and Access
  • Mental Health and Psychiatry
  • Mental Health Research Topics
  • Treatment of Major Depression

Among recent publications by Marder, notable papers include:

  • "Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments" (2023), published in Schizophrenia Research
  • "Rare coding variants in ten genes confer substantial risk for schizophrenia" (2022), published in Nature
  • "An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels" (2021), published in Pharmacopsychiatry
  • "The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research" (2020), published in Schizophrenia
  • "Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice" (2020), published in The Journal of Clinical Psychiatry

Marder's research has been disseminated frequently through several publication venues, including:

  • Schizophrenia Bulletin Open
  • UNC Libraries
  • Schizophrenia Bulletin
  • CNS Spectrums
  • Schizophrenia Research

Collaboration plays a significant role in Marder's work, with frequent coauthors including Michael F. Green, John M. Kane, Robert W. Buchanan, Junghee Lee, and Christoph U. Correll. These partnerships have contributed to advancing knowledge across multiple facets of psychiatric research and treatment.

Best Publications

  • Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

    Nancy C. Andreasen;William T. Carpenter;John M. Kane;Robert A. Lasser

  • The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

    Keith H. Nuechterlein;Michael F. Green;Robert S. Kern;Lyle E. Baade

  • Risperidone in the treatment of schizophrenia.

    Stephen R. Marder;Richard C. Meibach

  • The NIMH-MATRICS Consensus Statement on Negative Symptoms

    Brian Kirkpatrick;Wayne S Fenton;William T Carpenter;Stephen R Marder

  • Practice guideline for the treatment of patients with schizophrenia

    M. I. Herz;R. P. Liberman;T. H. McGlashan;J. A. Lieberman

  • Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria

    Michael F. Green;Keith H. Nuechterlein;James M. Gold;M Deanna

  • Physical Health Monitoring of Patients With Schizophrenia

    Stephen R. Marder;Susan M. Essock;Alexander L. Miller;Robert W. Buchanan

  • The Brief Negative Symptom Scale: Psychometric Properties

    Brian Kirkpatrick;Brian Kirkpatrick;Gregory P. Strauss;Linh Nguyen;Bernard A. Fischer;Bernard A. Fischer

  • Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

    Steven G. Potkin;Anutosh R. Saha;Mary J. Kujawa;William H. Carson

  • The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American Trials

    Stephen R. Marder;John M. Davis;Guy Chouinard

  • The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

    Robert S. Kern;Keith H. Nuechterlein;Michael F. Green;Lyle E. Baade

  • Novel antipsychotics: comparison of weight gain liabilities.

    Donna A. Wirshing;William C. Wirshing;Lisa Kysar;M. Andrew Berisford

  • Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

    Stephen R. Marder;Robert D. McQuade;Elyse Stock;Stephen Kaplita

  • The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

    Alan S. Bellack;Charles L. Bowden;Christopher R. Bowie;Matthew J. Byerly

  • Novel antipsychotics and new onset diabetes

    Donna A. Wirshing;Donna A. Wirshing;Brad J. Spellberg;Stephen M. Erhart;Stephen M. Erhart;Stephen R. Marder;Stephen R. Marder

  • Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia?

    Michael Foster Green;B. D. Marshall;William C. Wirshing;Donna Ames

  • The current conceptualization of negative symptoms in schizophrenia.

    Stephen R. Marder;Silvana Galderisi

  • The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments

    Robert W. Buchanan;Daniel C. Javitt;Stephen R. Marder;Nina R. Schooler

  • Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia

    Stephen R. Marder;Wayne Fenton

  • Social cognition in schizophrenia: relationships with neurocognition and negative symptoms.

    Mark J. Sergi;Yuri Rassovsky;Clifford Widmark;Clifford Widmark;Christopher Reist;Christopher Reist

Frequent Co-Authors

Jim Mintz
Jim Mintz The University of Texas Health Science Center at San Antonio
Michael F. Green
Michael F. Green University of California, Los Angeles
John M. Kane
John M. Kane Zucker Hillside Hospital
Robert S. Kern
Robert S. Kern University of California, Los Angeles
Richard S.E. Keefe
Richard S.E. Keefe Duke University
Jonathan K. Wynn
Jonathan K. Wynn University of California, Los Angeles
Jeffrey A. Lieberman
Jeffrey A. Lieberman Columbia University
Robert W. Buchanan
Robert W. Buchanan University of Maryland, Baltimore
Keith H. Nuechterlein
Keith H. Nuechterlein University of California, Los Angeles
George Bartzokis
George Bartzokis University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn't have to follow a single path. There are many related online degrees designed to meet a wide range of interests and professional goals in the healthcare field. For example, students interested in leadership roles may opt for a Master's in Healthcare Administration. Understanding mha degree cost is critical when considering this popular career move.

For registered nurses seeking specialized clinical roles, there are cheapest bsn to dnp programs that fast-track pathways to a Doctor of Nursing Practice (DNP). Aspiring pharmacists can also start their journey by researching online pharmacy school cost, ensuring their educational investment aligns with their career aspirations.

Additionally, the growing field of healthcare technology offers new opportunities. Attaining a health information management degree online opens doors to roles that bridge the gap between clinical care and data management. Each pathway offers unique advantages, flexibility, and financial options—making advanced healthcare education more accessible than ever.

Best Scientists Citing Stephen R. Marder

Trending Scientists

Recently Published Articles